Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
November 30, 2022 at 09:48 AM EST
Bluebird Bio Inc(NASDAQ: BLUE) has agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV)for $102 ...